aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.52727/2078-256X-2024-20-2-173-182ateroskleroz-1056Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSБиорезорбируемые скаффолды: прошлое и настоящее. Клинический пример 10-летнего наблюдения за пациентом с имплантированным стентом AbsorbBioresorbable scaffolds: past and present. Clinical example of a 10-year follow-up of a patient with an implanted Absorb stenthttps://orcid.org/0009-0000-9735-8073ЗагорулькоА. И.ZagorulkoA. I.

Алексей Иванович Загорулько – ассистент, зав. отделением

МИ; кафедра кардиологии, рентгенэндоваскулярных и гибридных методов диагностики и лечения; отделениее рентгенохирургических методов диагностики и лечения № 2

117152; Загородное шоссе, 18а, стр. 7; 117198; ул. Миклухо-Маклая, 6; Москва

Alexei I. Zagorulko, MD, assistant, Head of department

Medical institute; department of cardiology, endovascular surgery and hybrid methods of diagnosis and treatment; department of endovascular surgery

117152; 18a, bldg. 7, Zagorodnoye highw.; 117198; 6, Miklukho-Maklaya str.; Moscow

alexrus80@yandex.ruhttps://orcid.org/0000-0003-4925-7475ЧерняевМ. В.ChernyaevM. V.

Михаил Викторович Черняев – канд. мед. наук, ассистент, врач по рентгенэндоваскулярным диагностике и лечению

МИ; кафедра госпитальной хирургии с курсом детской хирургии

117198; ул. Миклухо-Маклая, 6; Москва

Mikhail V. Chernyaev, candidate of medical sciences, MD, assistant

Medical institute; department of hospital surgery with a course in pediatric surgery

117198; 6, Miklukho-Maklaya str.; Moscow

mikhailcherniaev@mail.ruКолединскийА. Г.KoledinskiyA. G.

Антон Геннадьевич Колединский — д-р мед. наук, зав. кафедрой, врач по рентгенэндоваскулярным диагностике и лечению

МИ; кафедра кардиологии, рентгенэндоваскулярных и гибридных методов диагностики и лечения

117198; ул. Миклухо-Маклая, 6; Москва

Anton G. Koledinskiy, doctor of medical sciences, head of the department

department of cardiology, endovascular surgery and hybrid methods of diagnosis and treatment endovascular surgery

117198; 6, Miklukho-Maklaya str.; Moscow

koledant@mail.ruГосударственное бюджетное учреждение здравоохранения г. Москвы Онкологический центр № 1 ГБУЗ «ГКБ им. С.С. Юдина ДЗМ»; Российский университет дружбы народовРоссияState budgetary healthcare institution of the city of Moscow “Moscow city clinical oncological hospital № 1”; Peoples’ Friendship University of RussiaRussian FederationРоссийский университет дружбы народовРоссияPeoples’ Friendship University of RussiaRussian Federation202405072024202173182Copyright © Загорулько А.И., Черняев М.В., Колединский А.Г., 20242024Загорулько А.И., Черняев М.В., Колединский А.Г.Zagorulko A.I., Chernyaev M.V., Koledinskiy A.G.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/1056

   Сегодня можно с уверенностью сказать, что чрескожное коронарное вмешательство является эффективным, малоинвазивным и безопасным методом лечения ИБС. Конечно, остаются сложные проблемы, которые требуют решения, к их числу относится использование металлических покрытых стентов, поскольку каркас стента навсегда остается в артерии. Идея создать биорезорбируемый каркас появилась более 20 лет назад, и одним из пионеров являлся скаффолд Absorb, который имплантировали в количестве более 150 000. За время существования данного стента провели большое количество исследований, выявили его сильные и слабые стороны и в итоге пришли к выводу о снятии с производства, но создание Absorb дало мощный толчок к изобретению новых видов скаффолдов.

   Today we can say with confidence that percutaneous coronary intervention is an effective, minimally invasive and safe method of treating coronary heart disease. As always complex problems require necessary solutions. One such challenge is the use of metallic covered stents because the stent frame remains permanently in the artery. The idea to create a bioresorbable scaffold appeared more than 20 years ago, and one of the pioneers was the Absorb scaffold, which was implanted in quantities of more than 150 000. During the existence of this stent, a large number of studies were carried out, strengths and weaknesses were identified and eventually came to the conclusion that it was discontinued, but creating Absorb gave a powerful drive to the invention of new types of scaffolds.

биоабсорбируемый скаффолд Absorb BVSметаллический покрытый стент DESbioabsorbable scaffolds Absorb BVSdrug-eluting metal stents Xience DESReferencesSerruys P.W., Ormiston J., van Geuns R.J., de Bruyne B., Dudek D., Christiansen E., Chevalier B., Smits P., McClean D., Koolen J., Windecker S., Whitbourn R., Meredith I., Wasungu L., Ediebah D., Veldhof S., Onuma Y. A polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5-year follow-up. J. Am. Coll. Cardiol., 2016; 67: 766–776. doi: 10.1016/j.jacc.2015.11.060Serruys P.W., Ormiston J., van Geuns R.J., de Bruyne B., Dudek D., Christiansen E., Chevalier B., Smits P., McClean D., Koolen J., Windecker S., Whitbourn R., Meredith I., Wasungu L., Ediebah D., Veldhof S., Onuma Y. A polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5-year follow-up. J. Am. Coll. Cardiol., 2016; 67: 766–776. doi: 10.1016/j.jacc.2015.11.060Onuma Y., Dudek D., Thuesen L., Webster M., Nieman K., Garcia-Garcia H.M., Ormiston J.A., Serruys P.W. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc. Interv., 2013; 6: 999–1009. doi: 10.1016/j.jcin.2013.05.017Onuma Y., Dudek D., Thuesen L., Webster M., Nieman K., Garcia-Garcia H.M., Ormiston J.A., Serruys P.W. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc. Interv., 2013; 6: 999–1009. doi: 10.1016/j.jcin.2013.05.017Brugaletta S., Radu M.D., Garcia-Garcia H.M., Heo J.H., Farooq V., Girasis C., Geuns R.J., Thuesen L., McClean D., Chevalier B., Windecker S., Koolen J., Rapoza R., Miquel-Hebert K., Ormiston J., Serruys P.W. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis, 2012; 221: 106–112. doi: 10.1016/j.atherosclerosis.2011.12.008Brugaletta S., Radu M.D., Garcia-Garcia H.M., Heo J.H., Farooq V., Girasis C., Geuns R.J., Thuesen L., McClean D., Chevalier B., Windecker S., Koolen J., Rapoza R., Miquel-Hebert K., Ormiston J., Serruys P.W. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis, 2012; 221: 106–112. doi: 10.1016/j.atherosclerosis.2011.12.008Brugaletta S., Heo J.H., Garcia-Garcia H.M., Farooq V., van Geuns R.J., de Bruyne B., Dudek D., Smits P., Koolen J., McClean D., Dorange C., Veldhof S., Rapoza R., Onuma Y., Bruining N., Ormiston J., Serruys P.W. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur. Heart. J., 2012; 33: 1325–1333. doi: 10.1016/j.amjcard.2012.01.071.Brugaletta S., Heo J.H., Garcia-Garcia H.M., Farooq V., van Geuns R.J., de Bruyne B., Dudek D., Smits P., Koolen J., McClean D., Dorange C., Veldhof S., Rapoza R., Onuma Y., Bruining N., Ormiston J., Serruys P.W. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur. Heart. J., 2012; 33: 1325–1333. doi: 10.1016/j.amjcard.2012.01.071.Загорулько А.И., Сидельников А.В., Шевчук И.В., Колединский А.Г. Эффективность и безопасность применения биорезорбируемых скаффолов Absorb BVS при лечении ишемической болезни сердца у пациентов, страдающих сахарным диабетом. Вестн. последиплом. мед. образования, 2019; 4: 11–14.Zagorulko A.I., Sidelnikov A.V., Shevchuk I.V., Koledinsky A.G. The efficacy and safety of Absorb BVS bioresorbable scaffolds in treatment of coronary heart disease in patients with diabetes mellitus. Post-Qualifying Medical Education Herald. 2019; 4: 11–14. (In Russ.)Ali Z.A., Serruys P.W., Kimura T., Gao R., Ellis S.G., Kereiakes D.J., Onuma Y., Simonton C., Zhang Z., Stone G.W. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet, 2017; 390: 760–772. doi: 10.1016/S0140-6736(17)31470-8Ali Z.A., Serruys P.W., Kimura T., Gao R., Ellis S.G., Kereiakes D.J., Onuma Y., Simonton C., Zhang Z., Stone G.W. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet, 2017; 390: 760–772. doi: 10.1016/S0140-6736(17)31470-8Ali Z.A., Gao R., Kimura T., Onuma Y., Kereiakes D.J., Ellis S.G., Chevalier B., Vu M.T., Zhang Z., Simonton C., Serruys P.W., Stone G. Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials. Circulation, 2018; 137: 464–479. doi: 10.1161/CIRCULATIONAHA.117.031843Ali Z.A., Gao R., Kimura T., Onuma Y., Kereiakes D.J., Ellis S.G., Chevalier B., Vu M.T., Zhang Z., Simonton C., Serruys P.W., Stone G. Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials. Circulation, 2018; 137: 464–479. doi: 10.1161/CIRCULATIONAHA.117.031843Kereiakes D.J., Ellis S.G., Metzger D.C., Caputo R.P., Rizik D.G., Teirstein P.S., Litt M.R., Kini A., Kabour A., Marx S., Popma J.J., Tan H.T., Ediebah D., Simonton C., Stone G.W. ABSORB III Investigators. Clinical outcomes before and after complete everolimus-eluting bioresorbable scaffold resorption: five-year follow-up from the ABSORB III trial. Circulation, 2019; 140: 1895–1903. doi: 10.1161/CIRCULATIONAHA.119.042584Kereiakes D.J., Ellis S.G., Metzger D.C., Caputo R.P., Rizik D.G., Teirstein P.S., Litt M.R., Kini A., Kabour A., Marx S., Popma J.J., Tan H.T., Ediebah D., Simonton C., Stone G.W. ABSORB III Investigators. Clinical outcomes before and after complete everolimus-eluting bioresorbable scaffold resorption: five-year follow-up from the ABSORB III trial. Circulation, 2019; 140: 1895–1903. doi: 10.1161/CIRCULATIONAHA.119.042584Kozuma K., Tanabe K., Hamazaki Y., Okamura T., Ando J., Ikari Y., Nakagawa Y., Kusano H., Ediebah D., Kimura T. ABSORB Japan Investigators. Long-term outcomes of absorb bioresorbable vascular scaffold vs. Everolimus-eluting metallic stent – a randomized comparison through 5 years in Japan. Circul. J., 2020; 84: 733–741. doi: 10.1253/circj.CJ-19-1184Kozuma K., Tanabe K., Hamazaki Y., Okamura T., Ando J., Ikari Y., Nakagawa Y., Kusano H., Ediebah D., Kimura T. ABSORB Japan Investigators. Long-term outcomes of absorb bioresorbable vascular scaffold vs. Everolimus-eluting metallic stent – a randomized comparison through 5 years in Japan. Circul. J., 2020; 84: 733–741. doi: 10.1253/circj.CJ-19-1184Stone G.W., Kimura T., Gao R., Kereiakes D.J., Ellis S.G., Onuma Y., Chevalier B., Simonton C., Dressler O., Crowley A., Ali Z.A., Serruys P.W. Time-varying outcomes with the absorb bioresorbable vascular scaffold during 5-year follow-up: a systematic meta-analysis and individual patient data pooled study. JAMA Cardiol., 2019; 4: 1261–1269. doi: 10.1001/jamacardio.2019.4101Stone G.W., Kimura T., Gao R., Kereiakes D.J., Ellis S.G., Onuma Y., Chevalier B., Simonton C., Dressler O., Crowley A., Ali Z.A., Serruys P.W. Time-varying outcomes with the absorb bioresorbable vascular scaffold during 5-year follow-up: a systematic meta-analysis and individual patient data pooled study. JAMA Cardiol., 2019; 4: 1261–1269. doi: 10.1001/jamacardio.2019.4101Verheye S., Ormiston J.A., Stewart J., Webster M., Sanidas E., Costa R., Chamie D., Abizaid A.S., Pinto I., Morrison L., Toyloy S., Bhat V., Yan J., Abizaid A. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc. Interv., 2014; 7: 89–99. doi: 10.1016/j.jcin.2013.07.007Verheye S., Ormiston J.A., Stewart J., Webster M., Sanidas E., Costa R., Chamie D., Abizaid A.S., Pinto I., Morrison L., Toyloy S., Bhat V., Yan J., Abizaid A. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc. Interv., 2014; 7: 89–99. doi: 10.1016/j.jcin.2013.07.007Abizaid A., Costa R.A., Schofer J., Ormiston J., Maeng M., Witzenbichler B., Botelho R., Costa J.R., Chamié D., Abizaid A., Castro J. , Morrison L., Toyloy S., Vinayak Bhat V., Yan J., Verheye S. Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions. JACC Cardiovasc. Interv., 2016; 9: 565–574. doi: 10.1016/j.jcin.2015.12.004Abizaid A., Costa R.A., Schofer J., Ormiston J., Maeng M., Witzenbichler B., Botelho R., Costa J.R., Chamié D., Abizaid A., Castro J. , Morrison L., Toyloy S., Vinayak Bhat V., Yan J., Verheye S. Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions. JACC Cardiovasc. Interv., 2016; 9: 565–574. doi: 10.1016/j.jcin.2015.12.004Nef H., Wiebe J., Boeder N., Dörr O., Bauer T., Hauptmann K.E., Latib A., Colombo A., Fischer D., Rudolph T., Foin N., Richardt G., Hamm C. A multicenter post-marketing evaluation of the Elixir DESolve(®) Novolimus-eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. Catheterizat. Cardiovasc. Interv., 2018; 92: 1021–1027. doi: 10.1002/ccd.27550Nef H., Wiebe J., Boeder N., Dörr O., Bauer T., Hauptmann K.E., Latib A., Colombo A., Fischer D., Rudolph T., Foin N., Richardt G., Hamm C. A multicenter post-marketing evaluation of the Elixir DESolve(®) Novolimus-eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. Catheterizat. Cardiovasc. Interv., 2018; 92: 1021–1027. doi: 10.1002/ccd.27550Mattesini A., Boeder N., Valente S., Löblich K., Dörr O., Secco G.G., Foin N., Caiazzo G., Ghione M., Gensini G.F., Porto I., Mario C.D., Nef H. Absorb vs. DESolve: an optical coherence tomography comparison of acute mechanical performances. EuroIntervention. 2016; 12: e566–е573. doi: 10.4244/EIJV12I5A96Mattesini A., Boeder N., Valente S., Löblich K., Dörr O., Secco G.G., Foin N., Caiazzo G., Ghione M., Gensini G.F., Porto I., Mario C.D., Nef H. Absorb vs. DESolve: an optical coherence tomography comparison of acute mechanical performances. EuroIntervention. 2016; 12: e566–е573. doi: 10.4244/EIJV12I5A96Mattesini A., Bartolini S., Sorini Dini C., Valente S., Parodi G., Stolcova M., Meucci F., Mario C.D. The DESolve novolimus bioresorbable scaffold: from bench to bedside. J. Thorac. Dis., 2017; 9 (Suppl. 9): S950–S958. doi: 10.21037/jtd.2017.07.25Mattesini A., Bartolini S., Sorini Dini C., Valente S., Parodi G., Stolcova M., Meucci F., Mario C.D. The DESolve novolimus bioresorbable scaffold: from bench to bedside. J. Thorac. Dis., 2017; 9 (Suppl. 9): S950–S958. doi: 10.21037/jtd.2017.07.25Abizaid A., Carrié D., Frey N., Lutz M., Weber-Albers J., Dudek D., Chevalier B., Weng S., Costa R., Anderson J., Stone G.W.; FANTOM II Clinical Investigators. 6-month clinical and angiographic outcomes of a novel radiopaque sirolimus-eluting bioresorbable vascular scaffold: the FANTOM II Study. JACC Cardiovasc. Interv., 2017; 10: 1832–1838. doi: 10.1016/j.jcin.2017.07.033Abizaid A., Carrié D., Frey N., Lutz M., Weber-Albers J., Dudek D., Chevalier B., Weng S., Costa R., Anderson J., Stone G.W.; FANTOM II Clinical Investigators. 6-month clinical and angiographic outcomes of a novel radiopaque sirolimus-eluting bioresorbable vascular scaffold: the FANTOM II Study. JACC Cardiovasc. Interv., 2017; 10: 1832–1838. doi: 10.1016/j.jcin.2017.07.033Simonsen J.K., Holck E.N., Carrié D., Frey N., Lutz M., Weber-Albers J., Dudek D., Daemen J., Dijkstra J., Maule C.F., Neghabat O., Lassen J.F., Anderson J., Christiansen E.H., Abizaid A., Ramsing Holm N.R. Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II study. Open Heart, 2019; 6:e000941. doi: 10.1136/openhrt-2018-000941Simonsen J.K., Holck E.N., Carrié D., Frey N., Lutz M., Weber-Albers J., Dudek D., Daemen J., Dijkstra J., Maule C.F., Neghabat O., Lassen J.F., Anderson J., Christiansen E.H., Abizaid A., Ramsing Holm N.R. Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II study. Open Heart, 2019; 6:e000941. doi: 10.1136/openhrt-2018-000941Waksman R., Lipinski M.J., Acampado E., Cheng Q., Adams L., Torii S., Gai J., Torguson R., Hellinga D., Joner M., Harder C., Zumstein P., Finn A.V., Kolodgie F.D., Virmani R., Waksman R. Comparison of acute thrombogenicity for metallic and polymeric bioabsorbable scaffolds: magmaris versus absorb in a porcine arteriovenous shunt model. Circul. Cardiovasc. Interv., 2017; 10: e004762. doi: 10.1161/CIRCINTERVENTIONS.116.004762Waksman R., Lipinski M.J., Acampado E., Cheng Q., Adams L., Torii S., Gai J., Torguson R., Hellinga D., Joner M., Harder C., Zumstein P., Finn A.V., Kolodgie F.D., Virmani R., Waksman R. Comparison of acute thrombogenicity for metallic and polymeric bioabsorbable scaffolds: magmaris versus absorb in a porcine arteriovenous shunt model. Circul. Cardiovasc. Interv., 2017; 10: e004762. doi: 10.1161/CIRCINTERVENTIONS.116.004762Erbel R., di Mario C., Bartunek J., Bonnier J., de Bruyne B., Eberli F.R., Erne P., Haude M., Heublein B., Horrigan M., Ilsley C., Böse D., Koolen J., Lüscher T.F., Weissman N., Waksman R. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet, 2007; 369: 1869–1875. doi: 10.1016/S0140-6736(07)60853-8Erbel R., di Mario C., Bartunek J., Bonnier J., de Bruyne B., Eberli F.R., Erne P., Haude M., Heublein B., Horrigan M., Ilsley C., Böse D., Koolen J., Lüscher T.F., Weissman N., Waksman R. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet, 2007; 369: 1869–1875. doi: 10.1016/S0140-6736(07)60853-8Haude M., Erbel R., Erne P., Verheye S., Degen H., Vermeersch P., Wijnbergen I., Weissman N., Prati F., Waksman R., Koolen J. Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. EuroIntervention, 2016; 12: e160–e166. doi: 10.4244/EIJ-D-15-00371Haude M., Erbel R., Erne P., Verheye S., Degen H., Vermeersch P., Wijnbergen I., Weissman N., Prati F., Waksman R., Koolen J. Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. EuroIntervention, 2016; 12: e160–e166. doi: 10.4244/EIJ-D-15-00371Haude M., Ince H., Toelg R., Lemos P.A., von Birgelen C., Christiansen E.H., Wijns W., Neumann F.J., Eeckhout E., Garcia-Garcia H.M., Waksman R. Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. EuroIntervention, 2020; 15: e1375–e1382. doi: 10.4244/EIJ-D-18-01000Haude M., Ince H., Toelg R., Lemos P.A., von Birgelen C., Christiansen E.H., Wijns W., Neumann F.J., Eeckhout E., Garcia-Garcia H.M., Waksman R. Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. EuroIntervention, 2020; 15: e1375–e1382. doi: 10.4244/EIJ-D-18-01000Verheye S., Wlodarczak A., Montorsi P., Bennett J., Torzewski J., Haude M., Vrolix M., Buck T., Aminian A., Schaaf R.J., Nuruddin A.A., Lee M.K.Y. Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry. EuroIntervention, 2020; 15: e1383–1386. doi: 10.4244/EIJ-D-18-01058Verheye S., Wlodarczak A., Montorsi P., Bennett J., Torzewski J., Haude M., Vrolix M., Buck T., Aminian A., Schaaf R.J., Nuruddin A.A., Lee M.K.Y. Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry. EuroIntervention, 2020; 15: e1383–1386. doi: 10.4244/EIJ-D-18-01058Zheng J.F., Qiu H., Tian Y., Hu X.Y., Luo T., Wu C., Tian Y., Tang Y., Song L., Li Li L., Xu L., Xu B., Gao R. Preclinical evaluation of a novel sirolimus-eluting iron bioresorbable coronary scaffold in porcine coronary artery at 6 months. JACC Cardiovasc. Interv., 2019; 12: 245–255. doi: 10.1016/j.jcin.2018.10.020Zheng J.F., Qiu H., Tian Y., Hu X.Y., Luo T., Wu C., Tian Y., Tang Y., Song L., Li Li L., Xu L., Xu B., Gao R. Preclinical evaluation of a novel sirolimus-eluting iron bioresorbable coronary scaffold in porcine coronary artery at 6 months. JACC Cardiovasc. Interv., 2019; 12: 245–255. doi: 10.1016/j.jcin.2018.10.020Qi Y., Qi H., He Y., Lin W., Li P., Qin L., Hu Y., Chen L., Liu Q., Sun H., Liu Q., Zhang G., Cui Sh., Hu J., Yu L., Zhang D., Ding J. Strategy of metal-polymer composite stent to accelerate biodegradation of iron-based biomaterials. ACS Appl. Mater. Interfaces., 2018; 10: 182–192. doi: 10.1021/acsami.7b15206Qi Y., Qi H., He Y., Lin W., Li P., Qin L., Hu Y., Chen L., Liu Q., Sun H., Liu Q., Zhang G., Cui Sh., Hu J., Yu L., Zhang D., Ding J. Strategy of metal-polymer composite stent to accelerate biodegradation of iron-based biomaterials. ACS Appl. Mater. Interfaces., 2018; 10: 182–192. doi: 10.1021/acsami.7b15206Vahl T.P., Gasior P., Gongora C.A., Ramzipoor K., Lee C., Cheng Y., McGregor J., Shibuya M., Estrada E.A., Conditt G.B., Kaluza G.L., Granada J.F. Four-year polymer biocompatibility and vascular healing profile of a novel ultrahigh molecular weight amorphous PLLA bioresorbable vascular scaffold: an OCT study in healthy porcine coronary arteries. Euro-Intervention, 2016; 12: 1510–1518. doi: 10.4244/EIJ-D-16-00308Vahl T.P., Gasior P., Gongora C.A., Ramzipoor K., Lee C., Cheng Y., McGregor J., Shibuya M., Estrada E.A., Conditt G.B., Kaluza G.L., Granada J.F. Four-year polymer biocompatibility and vascular healing profile of a novel ultrahigh molecular weight amorphous PLLA bioresorbable vascular scaffold: an OCT study in healthy porcine coronary arteries. Euro-Intervention, 2016; 12: 1510–1518. doi: 10.4244/EIJ-D-16-00308Jinnouchi H., Torii S., Sakamoto A., Kolodgie F.D., Virmani R., Finn A.V. Fully bioresorbable vascular scaffolds: lessons learned and future directions. Nat. Rev. Cardiol., 2019; 16: 286–304. doi: 10.1038/s41569-018-0124-7Jinnouchi H., Torii S., Sakamoto A., Kolodgie F.D., Virmani R., Finn A.V. Fully bioresorbable vascular scaffolds: lessons learned and future directions. Nat. Rev. Cardiol., 2019; 16: 286–304. doi: 10.1038/s41569-018-0124-7Lv X., Shen L., Wu Y., Ge L., Chen J., Yin J., Wang R., Ji M., Hong B., Ge J. Healing score of the Xinsorb scaffold in the treatment of de novo lesions: 6-month imaging outcomes. Int. J. Cardiovasc. Imaging., 2018; 34: 1009–1016. doi: 10.1007/s10554-018-1326-0Lv X., Shen L., Wu Y., Ge L., Chen J., Yin J., Wang R., Ji M., Hong B., Ge J. Healing score of the Xinsorb scaffold in the treatment of de novo lesions: 6-month imaging outcomes. Int. J. Cardiovasc. Imaging., 2018; 34: 1009–1016. doi: 10.1007/s10554-018-1326-0

The authors declare that there are no conflicts of interest present.